219873-03-7

Basic information

• Product Name: 6-(hydroxyMethyl)-2-naphthonitrile
• Synonyms: 6-(hydroxyMethyl)-2-naphthonitrile
• CAS NO: 219873-03-7
• Molecular Formula: C12H9NO
• Molecular Weight: 183.21
• Mol File: 219873-03-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 6-(hydroxyMethyl)-2-naphthonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(hydroxyMethyl)-2-naphthonitrile(219873-03-7)
• EPA Substance Registry System: 6-(hydroxyMethyl)-2-naphthonitrile(219873-03-7)

Safety Data

• Hazardous Substances Data: 219873-03-7(Hazardous Substances Data)

Upstream product

• 13720-06-4 2,6-dibromonaphthalene 
• 170737-46-9 6-bromo-naphthalene-2-carboxaldehyde 
• 773837-37-9 sodium cyanide 
• 100751-63-1 (6-bromo-2-naphthy)methanol 
• 149505-88-4 6-(Aminocarbonyl)-2-naphthalenecarboxylic acid,methyl ester 
• 69008-41-9 6-(Chlorocarbonyl)-2-naphthalenecarboxylic acid,methyl ester 
• 7568-08-3 naphthalene-2,6-dicarboxylic acid monomethyl ester 
• 840-65-3 dimethyl 2,6-naphthalenedicarboxylate 
• 5088-91-5 6-cyano-naphthalene-2-carboxylic acid methyl ester 

Downstream Products

• 56358-46-4 6-bromomethyl-2-naphthalenecarbonitrile 
• 823236-50-6 6-[(E)-2-(1-Cyclohexyl-3,4-dihydro-isoquinolin-7-yl)-vinyl]-naphthalene-2-carbonitrile 
• 823236-51-7 6-[(E)-2-(1-Phenyl-3,4-dihydro-isoquinolin-7-yl)-vinyl]-naphthalene-2-carbonitrile 
• 823236-47-1 6-[(E)-2-(3-Isopropoxy-phenyl)-vinyl]-naphthalene-2-carbonitrile 
• 371222-24-1 diethyl (6-cyano-2-naphthyl)methylphosphonate 
• 220299-36-5 6-[2-(Phenyl)ethyl]-2-naphthalenecarbonitrile 
• 220299-35-4 6-styryl-naphthalene-2-carbonitrile 

Relevant articles and documents

Substrate profiling of Finegoldia magna SufA protease, inhibitor screening and application to prevent human fibrinogen degradation and bacteria growth in vitro

SufA, which belongs to the subtilisin-like serine protease family, contains a non-canonical Asp-His-Ser catalytic triad. Under in vitro conditions, SufA is capable of human fibrinogen hydrolysis leading to inhibition of fibrin network formation, thus suggesting its important role in the development and progression of Finegoldia magna infections. In addition, it has been demonstrated that SufA can hydrolyze antibacterial peptides such as LL-37 and the chemokine MIG/CXCL 9, hence evading host defence mechanisms. Although the SufA protease from F. magna was discovered several years ago, its optimal substrate preference has not yet been identified. Considering the role of SufA, we have focused on the profiling of its substrate sequence preference spanning S1-S3 binding pockets using the FRET (fluorescence resonance energy transfer) approach. Next, based on the structure of the P1 residue of the developed substrate, we narrowed the inhibitor screening to the phosphonic analogues of amino acids containing an arginine-like side chain. Among all the compounds tested, only Cbz-6-AmNphthP(OPh)2 showed any inhibitory activity against SufA displaying k2/Ki value of 10 800 M -1 s-1. In addition, it prevented SufA-mediated human fibrinogen hydrolysis in vitro and exhibited potent antibacterial activity against F. magna, Staphylococcus aureus and Escherichia coli. Herein, we report on the substrate specificity, synthesis and kinetic evaluation of phosphonic inhibitors of SufA protease from F. magna which could help to establish its function in pathogenesis development and may lead to the elaboration of new antibacterial drugs.

Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties

A series of non-amide-linked 6-substituted-2-naphthamidine urokinase plasminogen activator (uPA) inhibitors are described. These compounds possess excellent binding activities and selectivities with significantly improved pharmacokinetic profiles versus p

Naphthamidine urokinase inhibitors

Compounds having the formula are inhibitors of urokinase and are useful in the treatment of diseases in which urokinase plays a role. Also disclosed are urokinase-inhibiting compositions, methods for the preparation of urokinase-inhibitors, and a method of inhibiting urokinase in a mammal.